ATH (ASX) PBT434 inhibits alpha- synuclein in the brain.

Originally posted by pivalde: ↑

skint, this is an important statement by ATH and looks to be based on the Finkelstein paper and the MSA mouse study but not to phase 1 study (???).
The other day we got this report (below) how CSF alpha-synuclein is not so good in monitoring the progress in PD. It is not a free paper so I made my conclusions only by the abstract. IMO the paper does not contradict the statement by ATH but I think that it is worth posting. Brain alpha-synuclein is important, not CSF alpha-synuclein.

Mov Disord. 2019 Jul 30. doi: 10.1002/mds.27806. [Epub ahead of print]
Longitudinal analyses of cerebrospinal fluid α-Synuclein in prodromal and early Parkinson's disease.
Mollenhauer B¹, Caspell-Garcia CJ², Coffey CS², Taylor P³, Singleton A⁴, Shaw LM⁵, Trojanowski JQ^6,⁷, Frasier M⁸, Simuni T⁹, Iranzo A¹⁰, Oertel W¹¹, Siderowf A^7,¹², Weintraub D¹², Seibyl J¹³, Toga AW¹⁴, Tanner CM¹⁵, Kieburtz K¹⁶, Chahine LM¹⁷, Marek K¹³, Galasko D¹⁸; PPMI study.
Author information

Abstract
BACKGROUND:
Aggregation of α-synuclein is central to the pathophysiology of PD. Biomarkers related to α-synuclein may be informative for PD diagnosis/progression.
OBJECTIVES:
To analyze α-synuclein in CSF in drug-naïve PD, healthy controls, and prodromal PD in the Parkinson's Progression Markers Initiative.
METHODS:
Over up to 36-month follow-up, CSF total α-synuclein and its association with MDS-UPDRS motor scores, cognitive assessments, and dopamine transporter imaging were assessed.
RESULTS:
The inception cohort included PD (n = 376; age [mean {standard deviation} years]: 61.7 [9.62]), healthy controls (n = 173; age, 60.9 [11.3]), hyposmics (n = 16; age, 68.3 [6.15]), and idiopathic rapid eye movement sleep behavior disorder (n = 32; age, 69.3 [4.83]). Baseline CSF α-synuclein was lower in manifest and prodromal PD versus healthy controls. Longitudinal α-synuclein decreased significantly in PD at 24 and 36 months, did not change in prodromal PD over 12 months, and trended toward an increase in healthy controls. The decrease in PD was not shown when CSF samples with high hemoglobin concentration were removed from the analysis. CSF α-synuclein changes did not correlate with longitudinal MDS-UPDRS motor scores or dopamine transporter scan.
CONCLUSIONS:
CSF α-synuclein decreases early in the disease, preceding motor PD. CSF α-synuclein does not correlate with progression and therefore does not reflect ongoing dopaminergic neurodegeneration. Decreased CSF α-synuclein may be an indirect index of changes in the balance between α-synuclein secretion, solubility, or aggregation in the brain, reflecting its overall turnover. Additional biomarkers more directly related to α-synuclein pathophysiology and disease progression and other markers to be identified by, for example, proteomics and metabolomics are needed. © 2019 International Parkinson and Movement Disorder Society.

Expand

Pivalde it is based on the human trial. Look at the last announcement on their site.

No.	Vol.	Price($)
103	101419021	0.4¢

No.

Vol.

Price($)

103

101419021

0.4¢

Price($)	Vol.	No.
0.5¢	24179262	14

Price($)

Vol.

No.

0.5¢

24179262

No.	Vol.	Price($)
103	101419021	0.004
63	62217433	0.003
18	33166014	0.002
16	108320102	0.001
0	0	0.000

No.

Vol.

Price($)

103

101419021

0.004

62217433

0.003

33166014

0.002

108320102

0.001

0.000

Price($)	Vol.	No.
0.005	24179262	14
0.006	21637365	19
0.007	26724705	23
0.008	28175438	30
0.009	17668789	11

Price($)

Vol.

No.

0.005

24179262

0.006

21637365

0.007

26724705

0.008

28175438

0.009

17668789

(20min delay)
Last 0.4¢		Change 0.000(0.00%)		Mkt cap ! $21.28M

Open	High	Low	Value	Volume
0.4¢	0.4¢	0.4¢	$420	105K

PBT434 inhibits alpha- synuclein in the brain., page-3

Perpetual sniffs TREOs beyond 4000ppm at Raptor play in Brazil

Quarterly and half yearly reports: Ampol, Fortescue and Newmont.

Acquisitions roundup: European Lithium, Diatreme Resources and SRJ Technologies

Bellevue aims for 45% production increase by FY 2028, announces $150M placement

Hexima shares rise 66% on proposed acquisition of AI player Real Thing Entertainment

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

PBT434 inhibits alpha- synuclein in the brain., page-3

Top Stories

Perpetual sniffs TREOs beyond 4000ppm at Raptor play in Brazil

Quarterly and half yearly reports: Ampol, Fortescue and Newmont.

Acquisitions roundup: European Lithium, Diatreme Resources and SRJ Technologies

Bellevue aims for 45% production increase by FY 2028, announces $150M placement

Hexima shares rise 66% on proposed acquisition of AI player Real Thing Entertainment

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News